Management of Anticoagulation Therapy in Patients With Thromboembolism in the Context of Renal Dysfunction: Challenging Cases and Practical Algorithms
Conclusions:
A significant change in anti-factor Xa (anti-Xa) levels—used for drug monitoring—should prompt an assessment of renal function. In nephrotic syndrome, anti-Xa levels should be closely monitored when there is a change in the status of nephrotic disease activity. In hemodialysis patients, enoxaparin at once daily reduced dosing should be considered with trough and peak anti-Xa levels monitoring.
Source: Journal of Pediatric Hematology Oncology - Category: Hematology Tags: Online Articles: Clinical and Laboratory Observations Source Type: research
More News: Cancer & Oncology | Children | Dialysis | Hematology | Hemodialysis | Laboratory Medicine | Lovenox | Nephrotic Syndrome | Pediatrics | Thrombosis | Urology & Nephrology